In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) reviews drug registration dossiers. The PMDA evaluates the safety, efficacy, and quality of new drugs before MHLW approval. Additionally, the MHLW makes the final decision based on PMDA’s assessment and recommendations.
